ClinicalTrials.gg
Not yet recruitingNCT07697612DURIOME-T2DUpdated Jul 13, 2026

Durian Consumption in Adults With Type 2 Diabetes Mellitus

An interventional study of Durian pulp in Type 2 Diabetes, sponsored by Singapore General Hospital. Not yet recruiting at 1 site in Singapore. Open to participants aged 21 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Singapore General Hospital · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
21 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Diabetes Mellitus, Type 2 by Singapore General Hospital — 5 open to participants now, 8 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Singapore General Hospital.

Planned enrollment
10th of 13
40 · median 150
Started
2026
the only one that year
No phase
13 of 15
5 open now
Registered
15th of 15
by date

Among the 15 studies in Diabetes Mellitus, Type 2 by Singapore General Hospital, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2026, is one of 13 with no phase, and was the 15th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

5 of the 15 studies in Diabetes Mellitus, Type 2 by Singapore General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 21 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Diabetes Mellitus, Type 2 by Singapore General Hospital, or all of them as a file.
02

Study summary

This single-arm clinical trial investigates the effects of daily durian consumption on the gut microbiome, host metabolome, and glucose metrics in adults with type 2 diabetes mellitus (T2DM). Forty adults with T2DM will undergo a pre-durian phase, a durian consumption phase, and a post-durian phase, each lasting 10 to 14 days. Participants will attend five visits at Singapore General Hospital for clinical assessments, continuous glucose monitoring, fasting blood collection, stool sample collection, and dietary and stool record submission. The study aims to determine whether durian consumption alters microbiome and metabolomic profiles and whether it affects glycemic measures in adults with T2DM.

Read the detailed description

Durian is a widely consumed tropical fruit with high fiber content and multiple bioactive compounds, including phenolics, flavonoids, carotenoids, and volatile sulfur compounds. Although animal and limited human studies suggest possible metabolic effects, the impact of durian consumption on gut microbiota and host metabolomic profiles in adults with type 2 diabetes mellitus remains unclear. This single-arm interventional study will enroll 40 adults with T2DM at Singapore General Hospital. Participants will complete five study visits over approximately 1.5 to 3 months. After screening, eligible participants will enter a pre-durian phase, a durian phase, and a post-durian phase, each lasting 10 to 14 days. During the durian phase, participants will consume 100 g of durian on Day 1 and 200 g daily from Day 2 onward for 10 to 14 days. Continuous glucose monitoring will be performed across study phases. Blood samples will be analyzed for clinical laboratory parameters, inflammatory markers, metabolomics, and genetic/epigenetic analyses. Stool samples will undergo metagenomic sequencing and metabolomic analysis. The study hypothesis is that durian consumption will result in significant changes in the gut microbiome and metabolome of individuals with T2DM without adversely affecting gluometric measures.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • Durian
  • Gut Microbiome
  • Metabolome
  • Continuous Glucose Monitoring
  • Precision Nutrition
  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 21 to 70 years.
  2. Diagnosis of type 2 diabetes mellitus.
  3. Agrees to consume durian for 2 weeks.
  4. 25 to 40 kg/m².

Exclusion criteria

Exclusion Criteria:

  1. Known or suspected intolerance or allergy to durian.
  2. Known skin reaction to adhesives used in a continuous glucose sensor.
  3. Uncontrolled diabetes ( greater than 8.5%).
  4. Severe hypertriglyceridemia (triglycerides greater than 4.5 mmol/L).
  5. Smoking.
  6. Previous gastrointestinal surgeries, including cholecystectomy, gastrectomy, bariatric surgery, or colectomy.
  7. Inflammatory bowel disease.
  8. less than 30 mL/min.
  9. greater than 3 times .
  10. AST greater than 3 times upper limit of normal.
  11. Liver cirrhosis.
  12. Significant alcohol consumption, defined as more than 20 g/day for women and more than 30 g/day for men.
  13. Pregnant, breastfeeding, or intending to conceive during the study.
  14. Current hemorrhoids or piles causing rectal bleeding during stool passage.
  15. Systemic use.
  16. Insulin use.
  17. Weight loss medications, including GLP-1 receptor agonists, orlistat, or phentermine.
  18. Antibiotic, prebiotic, probiotic, vitamin C, or traditional Chinese medicine use in the last 1 month.
  19. Uncontrolled thyroid disease.
  20. Any factor likely to limit adherence to study protocol, including dementia, substance abuse, poor appointment adherence, or family concerns regarding participation
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Durian pulp

    Adults with type 2 diabetes mellitus undergo a pre-durian observation phase, followed by daily durian consumption for 10 to 14 days, then a post-durian observation phase. All participants receive the same intervention and study procedures.

    Dietary Supplement: Durian pulp

Interventions

  • Dietary supplementDurian pulp

    Fresh durian pulp supplied by the study team. Participants consume 100 g on Day 1, then 200 g daily from Day 2 onward during the durian phase for 10 to 14 days. Participants record the timing and amount consumed each day.

06

What researchers measure

Primary outcomes

  1. Change in gut microbiome composition following durian consumption

    Gut microbiome composition will be assessed from stool samples using comprehensive metagenomic sequencing, comparing pre-durian, durian, and post-durian phases.

    Time frame: Baseline to end of durian phase, approximately 10 to 14 days; and through post-durian phase, approximately 20 to 28 days from baseline phase start

  2. Change in plasma metabolomic profile following durian consumption

    Plasma metabolomic changes will be assessed using mass spectrometry-based multi-omics profiling across study phases.

    Time frame: Baseline to end of durian phase, approximately 10 to 14 days; and through post-durian phase, approximately 20 to 28 days from baseline phase start

  3. Change in glucose metrics during and after durian consumption

    Continuous glucose monitoring data will be used to evaluate interstitial glucose patterns and gluometric parameters across study phases.

    Time frame: During pre-durian, durian, and post-durian phases, each approximately 10 to 14 days

Secondary outcomes

  1. Change in fasting plasma glucose

    Fasting glucose measured from blood samples across study visits.

    Time frame: Baseline to end of durian phase, approximately 10 to 14 days; and through post-durian phase, approximately 20 to 28 days from baseline phase start

  2. Change in fasting insulin

    Fasting insulin measured from blood samples across study visits.

    Time frame: Baseline to end of durian phase, approximately 10 to 14 days; and through post-durian phase, approximately 20 to 28 days from baseline phase start

  3. Change in lipid profile

    Lipid panel measured from fasting blood samples across study visits.

    Time frame: Baseline to end of durian phase, approximately 10 to 14 days; and through post-durian phase, approximately 20 to 28 days from baseline phase start

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — To comply with the institution's policy. Additional research sharing agreement would be needed

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Dec 2027, 16 months later.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 16 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Jul 13, 2026
StartEst.
Aug 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07697612
Responsible party
Sponsor
First posted
Jul 13, 2026
Start date
Aug 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 13, 2026

Study contacts

Hong Chang Tan, MD, PhD
Contact
tan.hong.chang@singhealth.com.sg
+65-6222 3322

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion